Belite Bio (subsidiary of Lin Bioscience) announced that its Phase 3 clinical trial for Tinlarebant (LBS-008), a treatment for adolescent Stargardt Disease (STGD1), has met its primary endpoint. Chairman Dr. Tom Lin expects to submit a New Drug Application (NDA) to the U.S. FDA in the first half of 2026.

Clinical Significance:

• Efficacy: Tinlarebant demonstrated a statistically significant reduction in the growth rate of DDAF (Decreased Autofluorescence) retinal atrophic lesions by 36% (p=0.0033) over 24 months. Post-hoc analysis further confirmed consistent efficacy with a p-value < 0.0001.
• Regulatory Milestones: The drug has already received Priority Review from China’s NMPA. Additionally, the UK’s MHRA has invited Belite to apply for Conditional Marketing Authorization (CMA) based on interim data from the "DRAGON" trial.
• Status: Tinlarebant holds Breakthrough Therapy, Fast Track, and Rare Pediatric Disease designations from the U.S. FDA, positioning it as a potential first-in-class treatment for this currently untreatable rare eye disease.

Resource: 仁新小金雞Belite Bio新藥三期解盲成功 明年H1向FDA申請藥證